Advertisement
ALGN vs BAX
Which Stock Would AI Choose? Align Technology (ALGN) vs. Baxter International (BAX) Stock Comparison
Key Takeaways
- Both ALGN and BAX have posted gains of around 14-15% over the past month, buoyed by healthcare sector momentum.
- ALGN demonstrates superior year-to-date performance at +21.43%, contrasting BAX's -4.97% decline.
- Upcoming Q1 2026 earnings reports highlight contrasts: ALGN poised for EPS (earnings per share) growth, while BAX anticipates a 43.6% YoY drop.
- ALGN's higher beta of 1.78 signals greater volatility than BAX's 0.62, appealing to different risk appetites.
- ALGN market cap (~$13B) exceeds BAX's (~$9B), with ALGN's TTM P/E (price-to-earnings ratio) at 33.5.
Introduction
Align Technology (ALGN) and Baxter International (BAX) represent distinct niches within the medtech sector, with ALGN dominating clear aligner orthodontics and BAX providing diversified hospital and renal care products. This stock comparison is timely amid recent healthcare rotations, where both have surged approximately 15% in the past month despite divergent longer-term trajectories. Traders seeking momentum plays and investors eyeing relative performance in a volatile market will find value in analyzing their business models, recent catalysts, and positioning ahead of Q1 2026 earnings. Understanding these dynamics aids informed decisions on sector exposure and trade-offs between growth and stability.
ALGN Overview and Recent Performance
Align Technology (ALGN), a leader in orthodontics, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners for aesthetic dentistry. In recent market activity, the stock has climbed 14% over the past month and 21% year-to-date, outperforming peers on strong trading days. Sentiment has been bolstered by anticipation for Q1 2026 earnings on April 29, with forecasts for EPS around $1.74-$2.26 and revenue near $1.02B, driven by Invisalign demand and scanner adoption. The company earned recognition as a LexisNexis Top 100 Global Innovator for the fifth year, underscoring sustained R&D strength. Broader influences include resilient consumer spending on elective procedures amid economic recovery.
BAX Overview and Recent Performance
Baxter International (BAX) is a global medtech firm offering products for hospital care, kidney therapy, and surgical equipment. Recent weeks have seen the stock rise 15% monthly, rebounding from year-to-date losses of nearly 5% and a 40% annual drop, amid sector tailwinds. Performance reflects mixed Q4 2025 results, with 8% sales growth to $2.97B but cautious 2026 guidance of flat organic sales and adjusted EPS of $1.85-$2.05. Q1 earnings on April 30 project EPS at $0.31, down sharply YoY, pressured by operational challenges. Sentiment hinges on cost discipline and restructuring efforts in a stabilizing healthcare environment.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of top-performing AI-powered trading bots from its library of 351 bots that trade thousands of tickers across stocks, ETFs, and crypto. Only the most suitable for current market conditions—based on real-time signals, risk management, and adaptability—earn a spot among the 25 featured. These bots deliver impressive stats, including annualized returns from +15% to +168%, win rates of 48%-88%, profit factors up to 11.7, and profit-to-drawdown ratios exceeding 20 in top cases. Spanning strategies like trend-following, long/short pairs, and multi-ticker portfolios with timeframes from minutes to weeks, they cater to diverse styles from conservative to aggressive. Traders can copy signals via virtual or brokerage agents to navigate volatility—explore the page to identify bots aligning with your risk profile and market outlook.
Head-to-Head Comparison
ALGN’s focused business model on innovative orthodontics contrasts BAX’s broader medtech diversification across hospitals and renal care, exposing ALGN to consumer elective demand while BAX ties to institutional spending. Growth drivers differ: ALGN benefits from Invisalign volume expansion (mid-single-digit projected), versus BAX’s flat organic sales outlook. Recent momentum is comparable short-term, but ALGN’s 1-year +4.7% edges BAX’s -40%, with higher P/E reflecting premium growth expectations. Risk factors include ALGN’s elevated beta amplifying market swings, against BAX’s defensive lower volatility. Sector exposure overlaps in healthcare but ALGN leans aesthetics, BAX essentials. Market sentiment favors ALGN’s earnings beat history and innovator status over BAX’s profitability pressures, highlighting trade-offs in growth versus stability.
Tickeron AI Verdict
Tickeron’s AI currently leans toward ALGN based on trend consistency, positive YTD momentum, and stronger earnings catalysts relative to BAX. ALGN’s relative positioning in recent market rotations and growth trajectory suggest higher probability of outperformance, though BAX offers stability for risk-averse strategies. Observable factors like volatility profiles and sector tailwinds inform this probabilistic edge, not a definitive outcome.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALGN is a Hold and BAX is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALGN’s FA Score shows that 0 FA rating(s) are green whileBAX’s FA Score has 1 green FA rating(s).
- ALGN’s FA Score: 0 green, 5 red.
- BAX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALGN’s TA Score shows that 3 TA indicator(s) are bullish while BAX’s TA Score has 5 bullish TA indicator(s).
- ALGN’s TA Score: 3 bullish, 7 bearish.
- BAX’s TA Score: 5 bullish, 5 bearish.
Price Growth
ALGN (@Pharmaceuticals: Other) experienced а -1.73% price change this week, while BAX (@Pharmaceuticals: Other) price change was +6.81% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.90%. For the same industry, the average monthly price growth was +0.96%, and the average quarterly price growth was +21.57%.
Reported Earning Dates
ALGN is expected to report earnings on Jul 29, 2026.
BAX is expected to report earnings on Jul 23, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-0.90% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| ALGN | BAX | ALGN / BAX | |
| Capitalization | 11.9B | 9.24B | 129% |
| EBITDA | 877M | 750M | 117% |
| Gain YTD | 6.174 | -6.338 | -97% |
| P/E Ratio | 27.86 | 87.85 | 32% |
| Revenue | 4.1B | 11.3B | 36% |
| Total Cash | 1.06B | 2.02B | 53% |
| Total Debt | 116M | 9.69B | 1% |
ALGN | BAX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 69 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 77 Overvalued | 95 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 67 | 94 | |
PRICE GROWTH RATING 1..100 | 60 | 63 | |
P/E GROWTH RATING 1..100 | 71 | 33 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALGN's Valuation (77) in the Medical Specialties industry is in the same range as BAX (95). This means that ALGN’s stock grew similarly to BAX’s over the last 12 months.
ALGN's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BAX (100). This means that ALGN’s stock grew similarly to BAX’s over the last 12 months.
ALGN's SMR Rating (67) in the Medical Specialties industry is in the same range as BAX (94). This means that ALGN’s stock grew similarly to BAX’s over the last 12 months.
ALGN's Price Growth Rating (60) in the Medical Specialties industry is in the same range as BAX (63). This means that ALGN’s stock grew similarly to BAX’s over the last 12 months.
BAX's P/E Growth Rating (33) in the Medical Specialties industry is somewhat better than the same rating for ALGN (71). This means that BAX’s stock grew somewhat faster than ALGN’s over the last 12 months.
| ALGN | BAX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 69% | 2 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 75% | 2 days ago 73% |
| Momentum ODDS (%) | 2 days ago 68% | 2 days ago 68% |
| MACD ODDS (%) | 2 days ago 74% | 2 days ago 41% |
| TrendWeek ODDS (%) | 2 days ago 71% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 77% | 2 days ago 60% |
| Advances ODDS (%) | 22 days ago 71% | 6 days ago 54% |
| Declines ODDS (%) | 9 days ago 73% | 10 days ago 64% |
| BollingerBands ODDS (%) | 2 days ago 68% | 2 days ago 61% |
| Aroon ODDS (%) | 2 days ago 72% | 2 days ago 66% |
Advertisement
BAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BAX has been loosely correlated with ALGN. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if BAX jumps, then ALGN could also see price increases.
| Ticker / NAME | Correlation To BAX | 1D Price Change % | ||
|---|---|---|---|---|
| BAX | 100% | +2.05% | ||
| ALGN - BAX | 65% Loosely correlated | +0.72% | ||
| LUNG - BAX | 53% Loosely correlated | -0.77% | ||
| STE - BAX | 51% Loosely correlated | +4.46% | ||
| SYK - BAX | 51% Loosely correlated | +4.20% | ||
| XRAY - BAX | 47% Loosely correlated | +0.82% | ||
More | ||||